P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia

Daniela Damiani, Mariagrazia Michieli, Angela Michelutti, Renato Fanin, Domenico Russo, Michele Baccarani

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph& CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29% chronic phase CML cases and in 16/23 (70) accelerated and blastic phase CML cases (P 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed PI 70 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph CML.

Original languageEnglish
Pages (from-to)289-294
Number of pages6
JournalLeukemia and Lymphoma
Volume17
Issue number3-4
DOIs
Publication statusPublished - 1995

Fingerprint

Anthracyclines
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Glycoproteins
Leukemia, Myeloid, Accelerated Phase
Idarubicin
Leukemia, Myeloid, Chronic Phase
Drug Therapy
Daunorubicin
Multiple Drug Resistance
Myeloid Cells
Pharmaceutical Preparations
Flow Cytometry
Stem Cells
Monoclonal Antibodies

Keywords

  • Anthracycline multidrug resistance
  • Chemotherapy
  • Chronic myeloid leukaemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. / Damiani, Daniela; Michieli, Mariagrazia; Michelutti, Angela; Fanin, Renato; Russo, Domenico; Baccarani, Michele.

In: Leukemia and Lymphoma, Vol. 17, No. 3-4, 1995, p. 289-294.

Research output: Contribution to journalArticle

Damiani, Daniela ; Michieli, Mariagrazia ; Michelutti, Angela ; Fanin, Renato ; Russo, Domenico ; Baccarani, Michele. / P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia. In: Leukemia and Lymphoma. 1995 ; Vol. 17, No. 3-4. pp. 289-294.
@article{7e13f92792b1425191d6f7e1055d2c2f,
title = "P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia",
abstract = "Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph& CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29{\%} chronic phase CML cases and in 16/23 (70) accelerated and blastic phase CML cases (P 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed PI 70 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph CML.",
keywords = "Anthracycline multidrug resistance, Chemotherapy, Chronic myeloid leukaemia",
author = "Daniela Damiani and Mariagrazia Michieli and Angela Michelutti and Renato Fanin and Domenico Russo and Michele Baccarani",
year = "1995",
doi = "10.3109/10428199509056834",
language = "English",
volume = "17",
pages = "289--294",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia

AU - Damiani, Daniela

AU - Michieli, Mariagrazia

AU - Michelutti, Angela

AU - Fanin, Renato

AU - Russo, Domenico

AU - Baccarani, Michele

PY - 1995

Y1 - 1995

N2 - Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph& CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29% chronic phase CML cases and in 16/23 (70) accelerated and blastic phase CML cases (P 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed PI 70 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph CML.

AB - Chronic myeloid leukaemia (CML) is a well known model of a disease refractory to chemotherapy, including anthracyclines and other drugs that are believed to be pumped out of the cells by a 170 Kd transmembrane glycoprotein (P170). In 35 cases of Ph& CML we investigated the reactivity of leukaemic cells to a P170-directed monoclonal antibody (MRK-16), by means of flow cytometry. P170 overexpression was found in 4/14 (29% chronic phase CML cases and in 16/23 (70) accelerated and blastic phase CML cases (P 0.01). The same cells were assayed for their ability to retain Daunorubicin and Idarubicin after 2-hours in vitro incubation with 1000 ng/ml of either drug. It was found that anthracycline cell concentration was negatively related with the degree of the reactivity to MRK-16. In accelerated and blastic phase, CML cells simultaneously expressed PI 70 and the stem cell related marker, CD34. These data confirm that Ph+ leukaemic cells overexpress P170, show that P170 overexpression is functionally relevant, and suggest that P170-related multidrug resistance may be an important factor for chemotherapy failure in Ph CML.

KW - Anthracycline multidrug resistance

KW - Chemotherapy

KW - Chronic myeloid leukaemia

UR - http://www.scopus.com/inward/record.url?scp=0028924560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028924560&partnerID=8YFLogxK

U2 - 10.3109/10428199509056834

DO - 10.3109/10428199509056834

M3 - Article

VL - 17

SP - 289

EP - 294

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3-4

ER -